Analogously, this prognostic effect of CD8CT constantly been confirmed in a variety of tumours such as epithelial ovarian cancer [16-17], breast cancer [18], prostate cancer [19], renal cell cancer [20], non-small cell lung cancer [21], colorectal cancer [22] and esophageal cancer [23], suggesting the great potential of tumour-infiltrating CD8+ T cells as a predictor for survival. This evidence concerns the gene CD8A and prostate carcinoma.